Immunologic Monitoring after Allogeneic Stem Cell Transplantation: T-SPOT.CMV and QuantiFERON-CMV, Are They the Same?

Interrater reliability: the kappa statistic

Marry L. McHugh · Biochemia Medica · 2012 · 17.4K citations · Full text

Reliability, Engineering, Data Reliability +13

Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic-Cell Transplantation

Francisco M. Marty, Per Ljungman, Roy F. Chemaly et al. · New England Journal of Medicine · 2017 · 1.1K citations · Full text

Definitions of Cytomegalovirus Infection and Disease in Transplant Patients for Use in Clinical Trials: Table 1.

Per Ljungman, Michael Boeckh, Hans H. Hirsch et al. · Clinical Infectious Diseases · 2016 · 916 citations · Full text

Viral Diagnostics, Immunology, Transplantation Medicine +18

Early Treatment with Ganciclovir to Prevent Cytomegalovirus Disease after Allogeneic Bone Marrow Transplantation

J. M. Goodrich, Motomi Mori, Curt A. Gleaves et al. · New England Journal of Medicine · 1991 · 607 citations · Full text

Pre-transplant cytomegalovirus (CMV) serostatus remains the most important determinant of CMV reactivation after allogeneic hematopoietic stem cell transplantation in the era of surveillance and preemptive therapy

Biju George, Nalini Pati, Nicole Gilroy et al. · Transplant Infectious Disease · 2010 · 175 citations

Cell Therapy, Pre-transplant Cytomegalovirus, Immunology +18